Save
CURRENT AND FUTURE DIRECTIONS FOR GRANULOSA CELL TUMOUR MANAGEMENT
ESGO eAcademy, Isabelle Ray-Coquard, 202840
WHAT IS THE STATE-OF-THE-ART FOR OVARIAN GERM CELL TUMOURS?
ESGO eAcademy, Jalid Sehouli, 202839
HEREDITARY GYNAECOLOGICAL CANCERS: PREVENTION AND ROLE OF PROPHYLACTIC SURGERIES
ESGO eAcademy, Ranjit Manchanda, 202843
HOW CAN WE ELIMINATE DEATHS IN HIGH RISK GTN?
ESGO eAcademy, Michael Seckl, 202838
STATE OF ART IN SCREENING OF GYNAECOLOGICAL CANCERS
ESGO eAcademy, Murat Gultekin, 202842
RECENT DEVELOPMENTS IN GTD AND MOLAR PREGNANCIES
ESGO eAcademy, Leon Massuger, 202837
THE IMPACT OF HEALTHY LIFE STYLE AND OBESITY ON PREVENTION OF GYNAECOLOGICAL CANCERS
ESGO eAcademy, Maria Kyrgiou, 202841
LAPAROSCOPIC VERSUS OPEN TREATMENT OF ENDOMETRIAL CANCER IN ELDERLY WOMEN
ESGO eAcademy, Ignacio Zapardiel Gultierrez, 202833
PREDICTIVE MARKERS IN CERVICAL CANCER
ESGO eAcademy, Cornelis D de Kroon, 203136
ELDERLY PATIENTS UNDERGOING SURGERY FOR OVARIAN OR CERVICAL CANCER: PERI-OPERATIVE ASSESSMENT AND SURGICAL CHOICES
ESGO eAcademy, Dina Kurdiani, 202832
PREDICTIVE MARKERS IN OVARIAN CARCINOMA
ESGO eAcademy, Alexandra Leary, 202835
FRAILTY EVALUATION AND MEDICAL TREATMENT OF ELDERLY POPULATION WITH GYNAECOLOGICAL MALIGNANCIES
ESGO eAcademy, Annamaria Ferrero, 202831
PREDICTIVE MARKERS IN ENDOMETRIAL CARCINOMA
ESGO eAcademy, Xavier Matias-Guiu, 202834
SUPPORTIVE CARE FOR WOMEN WITH GYNAECOLOGIC CANCER RECEIVING EXTERNAL BEAM RADIOTHERAPY AND BRACHYTHERAPY
ESGO eAcademy, Alina Sturdza, 202830
SUPPORTIVE CARE IN GYNECOLOGIC CANCER PATIENTS RECEIVING MEDICAL TREATMENT
ESGO eAcademy, Jørn Herrstedt, 202829
PERIOPERATIVE SUPPORTIVE CARE IN GYNECOLOGIC CANCER PATIENTS
ESGO eAcademy, Felix Hilpert, 202828
CERVICAL ADENOCARCINOMA IB1 AFTER RADICAL HYSTERECTOMY, POSITIVE LYMPHNODES - EVALUATION OF PERIAORTIC NODES, ADJUVANT THERAPY, MANAGEMENT OF OVARIES
ESGO eAcademy, Sebastien Gouy, 202824
CASE 3: DISTANT METASTASES, ENDOCRINE THERAPY, CHEMOTHERAPY
ESGO eAcademy, Guenter Emons, 202827
PLATINUM ELIGIBLE RECURRENT OVARIAN CANCER
ESGO eAcademy, Cristiana Sessa, 202820
CERVICAL CANCER IB1, 2CM TUMOR DIAMETER: SLN BIOPSY, MANAGEMENT IN REGARD TO ABSENCE/PRESENCE OF METASTATIC DISEASE
ESGO eAcademy, Alexander W. Reinthaller, 202823
CASE 2: ADVANCED, METASTATIC, TREATMENT WITH RADIOTHERAPY AND CHEMOTHERAPY
ESGO eAcademy, Melanie Powell, 202826
RECURRENT OVARIAN CANCER - ROLE OF SURGERY
ESGO eAcademy, Philipp Harter, 202819
SURGICAL MANAGEMENT IN PRIMARY OVARIAN CANCER
ESGO eAcademy, Giovanni Aletti, 202818
CERVICAL CANCER STAGE IB1, 3CM TUMOR DIAMETER: EVALUATION OF LYMPH NODES, RISK FACTORS AND THERAPEUTIC MANAGEMENT
ESGO eAcademy, Remi Nout, 202822
CASE 1: ADVANCED ENDOMETRIAL CANCER, AMENABLE TO SURGICAL RESECTION, ROLE OF NEOADJUVANT CHEMOTHERAPY
ESGO eAcademy, Frederic Amant, 202825
CURRENT CLINICALLY MEANINGFUL ASPECTS IN HEREDITARY UTERINE CANCER INCLUDING LYNCH SYNDROME
ESGO eAcademy, Uzi Beller, 202814
THE IMMUNOTHERAPY STORY
ESGO eAcademy, Lana Kandalaft, 202817
CURRENT CLINICALLY MEANINGFUL ASPECTS AND IMPORTANCE OF GERMLINE AND SOMATIC MUTATIONS IN HEREDITARY OVARIAN CANCER
ESGO eAcademy, Pauline Wimberger, 202813
THE PARP-I STORY
ESGO eAcademy, Andres Poveda, 202816
CURRENT CLINICALLY MEANINGFUL ASPECTS AND IMPORTANCE OF GERMLINE AND SOMATIC MUTATIONS IN HEREDITARY BREAST CANCER
ESGO eAcademy, Jan Lubinski, 202812
SURGICAL TRAILS
ESGO eAcademy, Andreas Du Bois, 202815
Conservative surgery for the treatment of granulosa cell tumors of the ovary: results from the MITO 9 study
ESGO eAcademy, Alice Bergamini, 202926
A COMPARATIVE STUDY OF TWO FOLLOW-UP STRATEGIES FOLLOWING TREATMENT OF ENDOMETRIAL CANCER BETWEEN AN ITALIAN AND A UK CENTRE
ESGO eAcademy, Valentina Ghirardi, 203531
HOW TO ASSESS RESECTABILITY AT PRIMARY SURGERY?
ESGO eAcademy, Anna Fagotti, 202808
WHICH ROLE CAN PATIENT REPORTED OUTCOMES AND QUALITY OF LIFE HAVE IN CLINICAL TRIALS
ESGO eAcademy, Remi Nout, 202811
Prospective Clinical Cohort Study For Efficacy Assessment Of Topical Treatment With Olivoleina On Post-Surgical Scars In Patients Undergoing Radiotherapy For Gyneacologic Cancers
ESGO eAcademy, Jesus Molero Vilchez, 202925
ANGIOGENESIS
ESGO eAcademy, Sandro Pignata, 202807
HOW TO INTEGRATE PATIENT REPORTED OUTCOME TOOLS IN THE EVERYDAY GYNAECOLOGICAL CANCER CLINIC
ESGO eAcademy, Galina Velikova, 202810
BRCA/HRD
ESGO eAcademy, Jonathan A Ledermann, 202806
OVERVIEW OF CURRENT DEVELOPMENTS IN MEASURING AND REPORTING PATIENT REPORTED OUTCOMES AND QUALITY OF LIFE IN GYNAECOLOGICAL CANCER
ESGO eAcademy, Lonneke van de Poll-Franse, 202809
MANAGEMENT OF RECURRENT DISEASE
ESGO eAcademy, Frederic Amant, 202799
CERVICAL CANCER IMMUNOTHERAPY TRIAL
ESGO eAcademy, Hans Nijman, 202804
CONSERVATIVE TREATMENT OF ENDOMETRIAL CANCER IN YOUNG WOMEN
ESGO eAcademy, Dimitrios Haidopoulos, 202798
OVARIAN CANCER IMMUNOTHERAPY TRIALS
ESGO eAcademy, Jonathan A Ledermann, 202803
RADICAL TREATMENT OF ENDOMETRIAL CANCER IN YOUNG WOMEN
ESGO eAcademy, Nicoletta Colombo, 202797
RISK FACTORS AND PATHOGENESIS OF ENDOMETRIAL CANCER IN YOUNG WOMEN
ESGO eAcademy, Vesna Kesic, 202796
PRINCIPLES OF IMMUNOTHERAPY
ESGO eAcademy, Christian Marth, 202801
Prognostic Value Of Lymph Node Ratio And Number Of Positive Inguinal Nodes In Patients With Vulvar Cancer
ESGO eAcademy, Richard Schwameis, 202924
ONCOLOGICAL MANAGEMENT AND PREGNANCY OUTCOMES IN WOMEN DIAGNOSED WITH CANCER DURING PREGNANCY: A 20-YEAR INTERNATIONAL COHORT STUDY OF 1170 PATIENTS
ESGO eAcademy, Frederic Amant, 202790
MECHANISMS OF RESISTANCE IN BRCA MUTATED TUMORS
ESGO eAcademy, Clare Scott, 202793
QUALITY OF LIFE WITH WEEKLY, DOSE-DENSE VERSUS STANDARD CHEMOTHERAPY FOR OVARIAN CANCER IN THE ICON8 STUDY
ESGO eAcademy, Sarah Blagden, 202788
CLINICALLY SIGNIFICANT LONG-TERM MAINTENANCE TREATMENT WITH OLAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)
ESGO eAcademy, Charlie Gourley, 202787
CLINICAL DEVELOPMENT OF OTHER NON PARP TARGETED THERAPIES
ESGO eAcademy, Cristiana Sessa, 202792
HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) FOR OVARIAN CANCER
ESGO eAcademy, Willemien J. Van Driel, 202786
ARIEL3: PHASE 3, RANDOMISED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA (OC)
ESGO eAcademy, Jonathan A Ledermann, 202785
UPDATE ON THE CLINICAL DEVELOPMENT OF PARP INHIBITORS
ESGO eAcademy, Iain McNeish, 202791
CLINICAL TRIALS IN PLATINUM-RESISTANT DISEASE
ESGO eAcademy, Mansoor Mirza, 202781
Vulvar Cancer In Ireland: Analysis Of The Irish National Cancer Registry Over A 20 Year Period
ESGO eAcademy, Ann Rowan, 203117
STRATEGIES FOR OVERCOMING RESISTANCE TO CHEMOTHERAPY
ESGO eAcademy, Sandro Pignata, 202780
PLATINUM-RESISTANT DISEASE: CURRENT STATUS
ESGO eAcademy, Nicole Concin, 202779
RANKL -BONES, SEX, AND BREAST CANCER
ESGO eAcademy, Josef Penninger, 202794
WHY ARE WE FAILING TO CURE OVARIAN CANCER?"
ESGO eAcademy, Christian Marth, 202795
GENERAL IMPLEMENTATION OF IGABT (TRAINING/ MEANS/HEALTH ECONOMICS/RESOURCE LIMITATIONS)
ESGO eAcademy, Christine Haie-Meder, 202775
WHEN, WHY AND HOW TO TEST MISMATCH REPAIR DEFICIENCY IN ENDOMETRIAL CANCER
ESGO eAcademy, Tjalling Bosse, 202778
IMAGE-GUIDED ADAPTIVE BRACHYTHERAPY VERSUS IMRT/STEREOTACTIC RADIOTHERAPY
ESGO eAcademy, Akila Viswanathan, 202774
WHEN, WHY AND HOW TO TEST FOR L1CAM AND P53 EXPRESSION IN ENDOMETRIAL CANCER
ESGO eAcademy, Alain G. Zeimet, 202777
CURRENT STATUS OF IMAGE-GUIDED BRACHYTHERAPY : ONCOLOGICAL RESULTS AND COMPLICATIONS
ESGO eAcademy, Jacob Lindegaard, 202773
WHEN, WHY AND HOW TO TEST POLE MUTATIONAL STATUS IN ENDOMETRIAL CANCER
ESGO eAcademy, David Church, 202776
Interval Between  Cytoreductive Surgery And Adjuvant Chemotherapy Is Associated With Overall Survival In  Patients With Advanced Ovarian Cancer
ESGO eAcademy, Maite Timmermans, 202923
Outcomes Of Robotic Radical Hysterectomy For Cervical Cancer In Comparison To Laparotomy ; A Population Based Study In The United States
ESGO eAcademy, Sabrina Piedimonte, 202922
TREATMENT OF ADVANCED DISEASE, INCLUDING MANAGEMENT OF MORBIDITY
ESGO eAcademy, Alexandra Taylor, 202769
IMPACT OF VAGINAL MORBIDITY ON SEXUALITY AFTER DEFINITIVE RADIOCHEMOTHERAPY IN LOCALLY ADVANCED CERVICAL CANCER PATIENTS
ESGO eAcademy, Kathrin Kirchheiner, 202772
ADJUVANT TREATMENT
ESGO eAcademy, Carien Creutzberg, 202768
PHYSICAL CONSEQUENCES OF GYNAECOLOGIC CANCER SURGERY AND THEIR IMPACT ON SEXUAL HEALTH
ESGO eAcademy, Michal Zikan, 202771
DIAGNOSTIC AND SURGICAL MANAGEMENT
ESGO eAcademy, Philippe Morice, 202767
SEXUAL HEALTH IN GYNAECOLOGIC CANCER PATIENTS - PSYCHO-SOCIAL CONSEQUENCES OF DIAGNOSIS AND TREATMENT
ESGO eAcademy, Moniek M ter Kuile, 202770
Cervical Cancer Relapse Rates In Patients With Para-Aortic Negitive PET Scans:A Five-Year Analysis In An Irish Gynaeoncology Centre
ESGO eAcademy, Ann Rowan, 202921
Discussion and Closing
ESGO eAcademy, Sandro Pignata, 202898
Patterns Of Lymph Node Metastases In Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study.
ESGO eAcademy, Lucas Minig, 202920
Future therapies
ESGO eAcademy, Kathleen Moore, 202897
Adjuvant management
ESGO eAcademy, Nicoletta Colombo, 202896
Long-Term Efficacy And Immunogenicity Of The 9-Valent Human Papillomavirus Vaccine: Final Analyses Of A Double-Blind, Randomized Clinical Study
ESGO eAcademy, Elmar A. Joura, 202919
Primary debulking strategy
ESGO eAcademy, Sven Mahner, 202895
Front-line Ovarian Cancer: Can we do better?: Welcome and introduction
ESGO eAcademy, Sandro Pignata, 202766
Mucinous Ovarian Cancer (MOC): What Is The Reproducibility Of The WHO Classification?
ESGO eAcademy, Mojgan Devouassoux-Shisheboran, 202918
Refinement Of High-Risk Endometrial-Cancer (HR-EC) Classification Using DNA Damage Response (DDR) Biomarkers: A Transportec Initiative
ESGO eAcademy, Aurélie AUGUSTE, 202917
PERIOPERATIVE CARE OF THE ELDERLY PATIENT
ESGO eAcademy, Karl Tamussino, 202765
MANAGEMENT OF ADVANCED STAGES AND RECURRENT DISEASE
ESGO eAcademy, Richard Poetter, 202761
Adverse Events After Hyperthermic Intraperitoneal Chemotherapy (HIPEC) For Stage III Ovarian Cancer: Phase III OVHIPEC Study
ESGO eAcademy, Simone Koole, 202916
MANAGEMENT OF EARLY STAGES
ESGO eAcademy, David Cibula, 202760
Perioperative Positioning Management In Gynecologic Cancer Surgery: A National NOGGO-AGO Intergroup Survey
ESGO eAcademy, Jenny Katharina Wagner, 202915
WHAT´S NEW IN ANESTHESIA FOR HIGH-RISK PATIENTS: WHAT SURGEONS NEED TO KNOW
ESGO eAcademy, Stephanie Suria, 202763
PATHOLOGY REPORT   
ESGO eAcademy, Maria Rosaria Raspollini, 202759
SHAPING NEW CLINICAL PRACTICE GUIDELINES
ESGO eAcademy, David Cibula, 202758
INITIATING ENHANCED RECOVERY: CHALLENGES AND OPPORTUNITIES
ESGO eAcademy, Lena Wijk, 202762
Hormonal And Fertility Outcome After Fertility Sparing Surgery And Chemotherapy For Ovarian Neoplasms: A Retrospective Study
ESGO eAcademy, Lorenzo Ceppi, 202914
MRI-Based Predictive Factors Of Axillary Lymph Node Metastases In Breast Cancer
ESGO eAcademy, David Atallah, 202913
Experience In Introducing Sentinel Lymph Node Biopsy In Early- Stage Vulva Cancer: A Single Institution Based Prospective Study
ESGO eAcademy, Ligita Paskeviciute Frøding, 202912
ESGO – A STORY OF SUCCESS
ESGO eAcademy, David Cibula, 202757
INTRODUCTION
ESGO eAcademy, Luis M. Chiva, 202756